Skip to content Skip to footer
Subscribe Now
MAGAZINE

PharmaShots Magazine-November-2025 Edition

Radiopharmaceuticals, once viewed as a niche scientific endeavor, are now revolutionizing the way we detect and treat cancer. By fusing the targeting precision of molecular medicine with the therapeutic strength of radiation, these compounds are unlocking new possibilities in oncology, bringing renewed hope to patients where conventional therapies often fall short From early detection to…
4 days ago

Read more

EXCLUSIVE

Exclusive: A Stimulating Dialogue with Edmund Ben Ami, Co-Founder & CEO of NeuraLight 

Shots:  Given the high variability and subjectivity of traditional clinical scales, there is an urgent need for objective biomarkers to assess CNS disease progression more reliably    NeuraLight is at the forefront of precision neurology, developing objective and sensitive biomarkers that bring greater accuracy and consistency to CNS research    In this exclusive conversation, Edmund…
October 14, 2025

Read more

VIEWPOINTS

Enhancing R&D Prowess in Oncology: Denis R. Beckford-Vera from Champions Oncology in Conversation with PharmaShots 

Shots:  The complexity of human physiology continues to challenge drug development, as conventional models often fail to provide critical insights, resulting in high attrition rates  Champions Oncology bridges this gap through patient-derived xenograft and ex vivo platforms built from real tumors, integrated with radiolabeled compounds for deeper R&D insights  Denis R. Beckford-Vera, Head of Radiopharmacology…
October 13, 2025

Read more

VIEWPOINTS

Breaking New Ground in Oncology: Leonard Mazur from Citius Pharmaceuticals in Conversation with PharmaShots 

Shots:   Citius Pharmaceuticals celebrates its first-ever FDA approval with Lymphir, a novel therapy for relapsed or refractory cutaneous T-cell lymphoma     In an exclusive conversation, Leonard Mazur, Co-Founder and CEO at Citius Pharmaceuticals, shares insights on Lymphir’s launch strategy and its potential impact on the oncology landscape    Leonard also highlights Mino-Lok, Citius’ innovative…
October 6, 2025

Read more

EVENTS

Discovery & Development Summit Asia 2025

Discovery & Development Summit Asia 2025 is Global Engage’s inaugural platform that brings together the Drug Discovery & Development, Nucleic Acid Therapeutics and Precision Medicine congresses. This summit allows the exploration of the full spectrum of therapeutic innovation, from early-stage discovery to clinical translation and commercialization. Attendees will gain insights into assay development, screening technologies,…
August 5, 2025

Read more

ThoughtSpot_Carla Adams3
THOUGHTSPOT

The Future of Personalized Medicine – How Pharma is Tailoring Treatments to Individuals

Personalized medicine is rapidly becoming a cornerstone of modern healthcare, promising to redefine how treatments are tailored to individual patients. Unlike traditional approaches, which often rely on a one-size-fits-all model, personalized medicine uses detailed information about a person’s genetic makeup, lifestyle, and environment to create more effective and precise treatments. This approach is gaining traction…
August 8, 2024

Read more

New Drug Designations - September 2023
INSIGHTS+

New Drug Designations – September 2023

Shots:  PharmaShots' designation report provides a concise overview of several drugs and their designations by the US FDA, the EU, and China. This month’s report includes 10 biological drugs, 15 small molecules, 5 cell and gene therapies, 4 devices, 1 vaccine and 1 microbiota  MicuRx’ Contezolid and Contezolid acefosamil, focused on the treatment of Diabetic…
October 16, 2023

Read more

Load more